Pfizer (PFE)
Pfizer Accounts Payable: 3.091B
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
PFE Accounts Payable Rankings
| Overall | 8th percentile | 3925 of 4283 |
| Sector | 1st percentile | 493 of 502 in Healthcare |
| Industry | 16th percentile | 21 of 25 in Drug Manufacturers - Major |
PFE Accounts Payable Range, Past 5 Years
| Minimum | 1.573B | Mar 2009 |
| Maximum | 4.37B | Dec 2009 |
| Average | 2.806B |
About Accounts Payable
Accounting terminology for money that a company owes to vendors for services or products that it purchased on credit. Accounts payable appear on the balance sheet as a current liability.
For example, accounts payable increases when a company purchases inventory "on account." When the money is repaid, accounts payable decreases.
YCharts takes accounts payable numbers directly from balance sheet line items.
Learn More
You may also be interested in these PFE related companies
PFE News
@SciGuy $DRRX I don't believe so; the fortunes of DURECT are tied to $PFE and Remoxy
about 29 minutes ago by SlownSteady
about 29 minutes ago by SlownSteady
@SCarolinaguy $DRRX licensed the drug to $PTIE; $PTIE licensed it to King and $PFE bought King; I think people might forget about $DRRX
about 49 minutes ago by SlownSteady
about 49 minutes ago by SlownSteady
@SlownSteady Sounds encouraging with $PFE supporting. What is the relationship? Surely their support would lead to approval
about 50 minutes ago by SCarolinaguy
about 50 minutes ago by SCarolinaguy
@SCarolinaguy $DRRX $PFE plans to resubmit the NDA. The company has other products; a recent filed trial triggered share price punishment
about 53 minutes ago by SlownSteady
about 53 minutes ago by SlownSteady
@SCarolinaguy $DRRX Only insiders know. CMC problems are usually resolved. $PFE will have new data and meet with the FDA
about 55 minutes ago by SlownSteady
about 55 minutes ago by SlownSteady
Still a Bear Market http://stks.co/41w8 $KFT $MCD $MRK $MSFT $PFE $KO
about 13 hours ago by LouisEbner
about 13 hours ago by LouisEbner
RT @Glopolon: Does it matter, they are next door to $PFE $AMRN /i live next to a lawyer. odds of being sued increased day they moved in. Hmm
about 3 days ago by ITradeforMe
about 3 days ago by ITradeforMe
RT @Glopolon $AMRN $PFE 'I wanna get close to you' Rose Royce http://stks.co/404L <Hmmmmmmmm!?$$$
about 3 days ago by Bleedblue
about 3 days ago by Bleedblue
$AMRN $PFE 'I wanna get close to you' Rose Royce http://stks.co/404H
about 3 days ago by Glopolon
about 3 days ago by Glopolon
@SomeGuy900 @christy155 $DRXX If $PFE gets a class 2 resubmission, they'll know in Q2/Q3 of next year; class one they'll know in Q1/Q2 '13
about 4 days ago by SlownSteady
about 4 days ago by SlownSteady
@SomeGuy900 @christy155 $DRXX The $PFE discussions with the FDA should be in Q3; I imagine they will resubmit in early 2013
about 4 days ago by SlownSteady
about 4 days ago by SlownSteady
@SomeGuy900 @christy155 The last comment from $DRRX management was that $PFE was getting ready to talk to the FDA about some more studies
about 4 days ago by SlownSteady
about 4 days ago by SlownSteady
@SomeGuy900 @christy155 $DRRX I have no idea what's going on. It's gone up 20 cents since I bought in. Maybe $PFE will talk with the FDA
about 4 days ago by SlownSteady
about 4 days ago by SlownSteady
@SomeGuy900 $DRRX $PFE will meet with the FDA, likely this summer. The good thing about the NDA is that the CRL was a CMC issue, chemistry
about 5 days ago by SlownSteady
about 5 days ago by SlownSteady
@rockchalk11 $ARNA Take a look at $DRRX; I bought it a few weeks ago at 72 cents. It's partnered, indirectly, with $PFE on Remoxy (a drug)
about 5 days ago by SlownSteady
about 5 days ago by SlownSteady
The Senate passed a bill that reauthorizes fees from drugmakers to fund the FDA. Likely to impact $PFE. http://stks.co/3zSI
about 5 days ago by ok123jump
about 5 days ago by ok123jump
@Urbane_Gorilla http://stks.co/3z5t $CYCC $CELG $BMY $REGN $PFE #ASCO12 checklist
about 6 days ago by biotech
about 6 days ago by biotech
Pfizer (PFE) Promotes Olivier Brandicourt to GM of Emerging Markets, Established Products Units
May 23, 7:31AM Street Insider
May 23, 7:31AM Street Insider
Pfizer (PF) Updates on Effect of Lyrica on Pain in Fibromyalgia Patients
May 18, 8:02AM Street Insider
May 18, 8:02AM Street Insider
Pfizer Exploratory Study Measures Effects Of Lyrica (pregabalin) On Brain Activity In Fibromyalgia Patients
May 18, 8:00AM Business Wire
May 18, 8:00AM Business Wire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| PFE | 22.04 | -0.14 | -0.63% | 167.18B |
| PFD | 13.85 | -0.04 | -0.29% | |
| PFCB | 51.26 | -0.12 | -0.23% | 1.090B |
| PFBCD | 12.32 | +0.28 | +2.33% | |
| PFBC | 12.18 | -0.14 | -1.14% | 162.50M |
| PFA | 14.94 | +0.14 | +0.95% | |
| PEZ | 28.26 | -0.36 | -1.26% | |
| PEY | 9.06 | -0.09 | -0.98% | |
| PETS | 11.26 | -0.21 | -1.83% | 233.30M |
| PETM | 64.46 | -0.05 | -0.08% | 7.089B |